Compare VRAX & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRAX | GXAI |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.3K | 5.4M |
| IPO Year | 2021 | 2022 |
| Metric | VRAX | GXAI |
|---|---|---|
| Price | $0.61 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 537.1K | 135.0K |
| Earning Date | 11-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.35 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,933,030.00 |
| Revenue This Year | N/A | $462.16 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 47901.74 |
| 52 Week Low | $0.10 | $0.34 |
| 52 Week High | $13.19 | $5.26 |
| Indicator | VRAX | GXAI |
|---|---|---|
| Relative Strength Index (RSI) | 21.31 | 46.09 |
| Support Level | $0.15 | $0.41 |
| Resistance Level | $1.57 | $0.52 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 10.47 | 49.14 |
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.